Marlene McLennan - Aspira Womens Interim Officer
| AWH Stock | USD 0.81 0.05 6.58% |
Insider
Marlene McLennan is Interim Officer of Aspira Womens Health
| Age | 54 |
| Address | Building III, Austin, TX, United States, 78738 |
| Phone | 512 519 0400 |
| Web | https://aspirawh.com |
Aspira Womens Management Efficiency
The company has Return on Asset of (1.8571) % which means that on every $100 spent on assets, it lost $1.8571. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (7.2345) %, meaning that it generated no profit with money invested by stockholders. Aspira Womens' management efficiency ratios could be used to measure how well Aspira Womens manages its routine affairs as well as how well it operates its assets and liabilities. The Aspira Womens' current Return On Equity is estimated to increase to 7.41, while Return On Tangible Assets are forecasted to increase to (2.53). As of now, Aspira Womens' Fixed Asset Turnover is increasing as compared to previous years. The Aspira Womens' current Asset Turnover is estimated to increase to 1.53, while Total Assets are projected to decrease to under 5.9 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| William Annett | OncoCyte Corp | 70 | |
| Yaron Eldad | Evogene | 59 | |
| Ekkehard MD | OncoCyte Corp | N/A | |
| Andrew Arno | OncoCyte Corp | 59 | |
| Lyndal Hesterberg | OncoCyte Corp | N/A | |
| Cavan Redmond | OncoCyte Corp | 58 | |
| Tony Kalajian | OncoCyte Corp | N/A | |
| Thomas MD | Electrocore LLC | 72 | |
| MD MBA | Electrocore LLC | 61 | |
| Andrew Last | OncoCyte Corp | 59 | |
| Padma Sundar | OncoCyte Corp | N/A | |
| Jackie Dorsky | Electrocore LLC | N/A | |
| Dotan Borenstein | Evogene | N/A | |
| Gisela Paulsen | OncoCyte Corp | 58 | |
| Sara Riordan | OncoCyte Corp | N/A | |
| Iain Strickland | Electrocore LLC | N/A | |
| CCFP DipSportMed | Evolus Inc | 60 | |
| Sandra Beaver | Evolus Inc | 46 | |
| Anish John | OncoCyte Corp | 54 | |
| Daniel Goldberger | Electrocore LLC | 65 | |
| Melinda Griffith | OncoCyte Corp | 64 | |
Management Performance
| Return On Equity | -7.23 | ||||
| Return On Asset | -1.86 |
Aspira Womens Health Leadership Team
Elected by the shareholders, the Aspira Womens' board of directors comprises two types of representatives: Aspira Womens inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aspira. The board's role is to monitor Aspira Womens' management team and ensure that shareholders' interests are well served. Aspira Womens' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aspira Womens' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michelle Snider, Senior Operations | ||
| Ryan MD, Chief Officer | ||
| Emily Granger, Director Marketing | ||
| Torsten Hombeck, Senior CFO | ||
| Robert CPA, Chief Officer | ||
| Michael Newton, VP Commercial | ||
| Marlene McLennan, Interim Officer | ||
| John Kallassy, Interim Officer | ||
| Jody Berry, Chief Officer | ||
| Sean Rowe, VP Technology | ||
| Nicole CPA, CEO President | ||
| Gregory Richard, Sr Devel | ||
| Valerie Palmieri, Ex Chairwoman | ||
| Minh Merchant, General Secretary | ||
| Charles MD, Interim Officer | ||
| MD JD, President |
Aspira Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Aspira Womens a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -7.23 | ||||
| Return On Asset | -1.86 | ||||
| Profit Margin | (1.79) % | ||||
| Operating Margin | (1.81) % | ||||
| Current Valuation | 13.51 M | ||||
| Shares Outstanding | 16.67 M | ||||
| Shares Owned By Insiders | 30.94 % | ||||
| Shares Owned By Institutions | 13.89 % | ||||
| Number Of Shares Shorted | 516.18 K | ||||
| Price To Earning | 16.82 X |
Currently Active Assets on Macroaxis
When determining whether Aspira Womens Health offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aspira Womens' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aspira Womens Health Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aspira Womens Health Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aspira Womens Health. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aspira Womens. If investors know Aspira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aspira Womens listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.15) | Revenue Per Share 0.801 | Quarterly Revenue Growth (0.03) | Return On Assets (1.86) | Return On Equity (7.23) |
The market value of Aspira Womens Health is measured differently than its book value, which is the value of Aspira that is recorded on the company's balance sheet. Investors also form their own opinion of Aspira Womens' value that differs from its market value or its book value, called intrinsic value, which is Aspira Womens' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aspira Womens' market value can be influenced by many factors that don't directly affect Aspira Womens' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aspira Womens' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aspira Womens is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aspira Womens' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.